Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.01, for a total value of $5,006,595.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $21,350,756.13. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

United Therapeutics Stock Up 2.0%

Shares of United Therapeutics stock opened at $531.82 on Wednesday. The business has a 50 day moving average of $492.27 and a 200 day moving average of $470.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The company has a market cap of $23.31 billion, a PE ratio of 19.06, a P/E/G ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.19 earnings per share. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of UTHR. Rockefeller Capital Management L.P. lifted its position in United Therapeutics by 10.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 127 shares during the period. Corient Private Wealth LLC grew its holdings in United Therapeutics by 13.5% in the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock worth $9,379,000 after purchasing an additional 2,289 shares during the period. Rehmann Capital Advisory Group grew its holdings in United Therapeutics by 9.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after purchasing an additional 324 shares during the period. Tobam increased its stake in shares of United Therapeutics by 28.9% during the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock valued at $4,803,000 after purchasing an additional 2,211 shares in the last quarter. Finally, Wick Capital Partners LLC purchased a new position in shares of United Therapeutics during the fourth quarter valued at approximately $297,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Finally, Wells Fargo & Company increased their target price on United Therapeutics from $466.00 to $486.00 and gave the stock an “equal weight” rating in a research report on Monday. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $549.91.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.